IP Library Granted Patent US 9,669,025
Granted Patent B2
US 9,669,025 · App. 14/831,100 · Granted Jun 6, 2017

Use of levocetirizine and montelukast in the treatment of vasculitis

Inventor: Bruce Chandler May (Santa Barbara, CA)
Assignee: INFLAMMATORY RESPONSE RESEARCH, INC.
A61K31/495A61K31/136A61K31/454A61K31/47A61K31/496A61K31/519A61K31/56A61K31/573A61K39/395A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,669,025
App. No.
14/831,100
Granted
Jun 6, 2017
Kind
B2
Abstract

The embodiments described herein include methods and formulations for treating vasculitis. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of levocetirizine and montelukast to a patient in need. The methods and formulations can comprise conventional and/or modified-release elements, providing for drug delivery to the patient.

Claims (15)

1. A method of treating vasculitis in a patient in need thereof comprising administering to the patient an effective amount of a combination of levocetirizine and montelukast, wherein vasculitis comprises Henoch Schonlein Purpura.

2. The method of claim 1 , wherein the combination is administered in a sequential manner.

3. The method of claim 1 , wherein the combination is administered in a substantially simultaneous manner.

4. The method of claim 1 , wherein the combination is administered at the onset of symptoms.

5. The method of claim 1 , wherein the combination is administered to the patient by one or more of the routes consisting of enteral, intravenous, intraperitoneal, inhalation, intramuscular, subcutaneous and oral.

6. The method of claim 5 , wherein the levocetirizine and montelukast are administered by the same route.

7. The method of claim 1 , wherein the combination is administered at the onset of symptoms.

8. The method of claim 1 , further comprising the administration of an active agent.

9. The method of claim 8 , wherein the active agent is a glucocorticoid.

10. The method of claim 8 , wherein the active agent is a steroidal anti-inflammatory agent.

11. The method of claim 8 , wherein the active agent is a non-steroidal anti-inflammatory agent.

12. The method of claim 8 , wherein the active agent is an antihistamine.

13. The method of claim 8 , wherein the active agent is a cytotoxic drug.

14. The method of claim 8 , wherein the active agent is an immunosuppressive agent.

15. The method of claim 8 , wherein the active agent is a monoclonal antibody.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 5, 2018
From: MAY, BRUCE CHANDLER
To: IRR, INC.
Reel/Frame 047724/0470 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 3, 2015
From: MAY, BRUCE CHANDLER
To: INFLAMMATORY RESPONSE RESEARCH, INC.
Reel/Frame 036486/0837 →
Continuity (3)
Continuation PCTUS2014021732 · Mar 7, 2014
Provisional Application 61780380 · Mar 13, 2013
Related Publication 20150352101A1 · Dec 10, 2015